Dr. Onland was born in a rural area of the Netherlands. He graduated as a medical doctor in 1999 and started his paediatric training in 2002 at the Emma Children’s Hospital of the Academic Medical Center (AMC) in Amsterdam. He spent one year at the Children’s Hospital Los Angeles to do research. While subspecializing in Neonatology, he wrote his PhD thesis “Bronchopulmonary Dysplasia and Perinatal Glucocorticoids in Preterm Infants: Changing practice based on evidence”; his PhD supervisors were Prof. Offringa and Prof. van Kaam.
Dr. Onland is currently the PI of the SToP-BPD trial (Systemic hydrocortisone to prevent bronchopulmonary dysplasia in preterm infants) and a co-PI in multiple (inter)national multicentre clinical trials. His research focusses on prevention and management of bronchopulmonary dysplasia, including oxygen saturation targeting and ventilation strategies, management of PDA and caffeine and steroid treatment. Working as staff neonatologist in the Emma Children’s Hospital Amsterdam UMC, he chairs the Neonatology Network Netherlands (N3) since 2018. N3 is the Dutch national organisation initiating, facilitating and organizing neonatal research, benchmarking and guideline developments (www.neonatologynetwork.eu).
Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/?term=Onland%20W%5BAuthor%
